{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:02:49Z","timestamp":1789552969283,"version":"build-2803163510"},"reference-count":47,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Chemoresistance in breast cancer remains a major clinical challenge, fueled by robust antioxidant defenses that neutralize cisplatin-induced oxidative stress through the NRF2\/SLC7A11\/GPX4 pathway in luminal breast cancer cells. This study examined camel milk whey protein (CMP), a bioactive fraction rich in lactoferrin and antioxidant peptides, as a redox-modulating chemosensitizer to boost cisplatin efficacy in MCF-7 cells while simultaneously assessing treatment selectivity in non-tumorigenic MCF-12A mammary epithelial cells. Cells were treated for 24 h with CMP (at 200 and 600 ng\/mL, designated as P1 and P2) and cisplatin (25 \u00b5M), both individually and in combination. Cell viability was evaluated via the MTT assay, and the mRNA expression levels of NRF2, GPX4, and SLC7A11 were quantified using RT-qPCR. Bliss independence synergy analysis was applied to the MTT datasets, and a protein\u2013protein interaction network was constructed via STRING (v12.0). Furthermore, the clinical significance of the NRF2\/SLC7A11\/GPX4 axis was explored through Kaplan\u2013Meier survival analysis (using KM Plotter), alongside genomic profiling via cBioPortal (TCGA PanCancer Atlas). Co-treatment with CMP and cisplatin significantly diminished MCF-7 cell viability compared to single-agent treatments, driven by the coordinated downregulation of NRF2, SLC7A11, and GPX4. Bliss independence modeling confirmed synergistic cytotoxicity for both the P1 + Cis and P2 + Cis combinations. Conversely, MCF-12A cells showed no intrinsic cytotoxicity (CC50 &gt; 600 ng\/mL) and displayed a distinct transcriptional profile following cisplatin exposure, marked by the upregulation of GPX4 and SLC7A11. In silico evaluations further reinforced the clinical relevance of this axis, revealing that elevated NRF2 and SLC7A11 expression correlates with poor relapse-free survival and recurrent genomic alterations across breast cancer cohorts. Ultimately, these results demonstrate that CMP disrupts the NRF2\/SLC7A11\/GPX4 antioxidant axis in cancer cells, offering a promising, selective strategy to enhance cisplatin sensitivity while safeguarding healthy tissues.<\/jats:p>","DOI":"10.3390\/ijms27188241","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:06:37Z","timestamp":1789549597000},"page":"8241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NRF2\/SLC7A11\/GPX4 Antioxidant Axis Suppression by Camel Milk Whey Protein Sensitizes MCF-7 Breast Cancer Cells to Cisplatin"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8241-1596","authenticated-orcid":false,"given":"\u0130lkay","family":"Civelek","sequence":"first","affiliation":[{"name":"Department of Biotechnology, Science Faculty, Ni\u011fde \u00d6mer Halisdemir University, Ni\u011fde 51240, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.14366\/usg.16030","article-title":"Molecular subtypes and imaging phenotypes of breast cancer","volume":"35","author":"Cho","year":"2016","journal-title":"Ultrasonography"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41523-025-00723-0","article-title":"The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype","volume":"11","author":"Turova","year":"2025","journal-title":"npj Breast Cancer"},{"key":"ref_5","first-page":"3147","article-title":"The story of MCF-7 breast cancer cell line: 40 years of experience in research","volume":"35","author":"Raica","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhou, J., Kang, Y., Chen, L., Wang, H., Liu, J., Zeng, S., and Yu, L. (2020). The drug-resistance mechanisms of five platinum-based antitumor agents. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00343"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/DDDT.S509357","article-title":"Vaccarin ameliorates renal fibrosis by inhibiting ferroptosis via Nrf2\/SLC7A11\/GPX4 signaling pathway","volume":"19","author":"Cui","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104050","DOI":"10.1016\/j.redox.2026.104050","article-title":"NRF2: Master regulator of cellular homeostasis and therapeutic vulnerability in cancer","volume":"90","author":"Chen","year":"2026","journal-title":"Redox Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","article-title":"Cystine transporter SLC7A11\/xCT in cancer: Ferroptosis, nutrient dependency, and cancer therapy","volume":"12","author":"Koppula","year":"2021","journal-title":"Protein Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41419-024-07237-w","article-title":"Conjugated fatty acids drive ferroptosis through chaperone-mediated autophagic degradation of GPX4 by targeting mitochondria","volume":"15","author":"Hirata","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.canlet.2021.09.033","article-title":"SLC7A11\/xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells","volume":"522","author":"Yadav","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2291855","DOI":"10.1080\/15384047.2023.2291855","article-title":"The amino acid transporter SLC7A11 expression in breast cancer","volume":"25","author":"Nath","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.62347\/GSBB1090","article-title":"The dual role of SLC7A11 in tumor drug resistance: Mechanisms, challenges, and therapeutic potential","volume":"15","author":"Guo","year":"2025","journal-title":"Am. J. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.55549\/zbs.1581366","article-title":"Cisplatin in Chemotherapy","volume":"6","author":"Erdem","year":"2025","journal-title":"Zeugma Biol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mariconda, A., Ceramella, J., Catalano, A., Saturnino, C., Sinicropi, M.S., and Longo, P. (2025). Cisplatin, the timeless molecule. Inorganics, 13.","DOI":"10.3390\/inorganics13070246"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hill, D.P., Harper, A., Malcolm, J., McAndrews, M.S., Mockus, S.M., Patterson, S.E., Reynolds, T., Baker, E.J., Bult, C.J., and Chesler, E.J. (2019). Cisplatin-resistant triple-negative breast cancer subtypes: Multiple mechanisms of resistance. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6278-9"},{"key":"ref_18","first-page":"665","article-title":"Enhancement of cisplatin sensitivity in human breast cancer MCF-7 cell line through BiP and 14-3-3\u03b6 co-knockdown","volume":"45","author":"Safarian","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17639","DOI":"10.1038\/s41598-019-54065-6","article-title":"The balance between NRF2\/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells","volume":"9","author":"Silva","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"113551","DOI":"10.1016\/j.bcp.2019.06.007","article-title":"The potential use of natural products to negate hepatic, renal and neuronal toxicity induced by cancer therapeutics","volume":"173","author":"Karademir","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105531","DOI":"10.1016\/j.fbio.2024.105531","article-title":"An updated comprehensive review of camel milk: Composition, therapeutic properties, and industrial applications","volume":"62","author":"Khaliq","year":"2024","journal-title":"Food Biosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e71638","DOI":"10.1002\/fsn3.71638","article-title":"Camel Milk as a Functional Food: Nutritional Composition, Health-Promoting Benefits, and Safety Considerations","volume":"14","author":"Bereda","year":"2026","journal-title":"Food Sci. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Khan, M.Z., Xiao, J., Ma, Y., Ma, J., Liu, S., Khan, A., Khan, J.M., and Cao, Z. (2021). Research development on anti-microbial and antioxidant properties of camel milk and its role as an anti-cancer and anti-hepatitis agent. Antioxidants, 10.","DOI":"10.3390\/antiox10050788"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00296-023-05516-x","article-title":"Potential role of camel, mare milk, and their products in inflammatory rheumatic diseases","volume":"44","author":"Kocyigit","year":"2024","journal-title":"Rheumatol. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1177\/1534735418786000","article-title":"Therapeutic effect of camel milk and its exosomes on MCF7 cells in vitro and in vivo","volume":"17","author":"Badawy","year":"2018","journal-title":"Integr. Cancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Badawy, A.A., Othman, R.Q.A., and El-Magd, M.A. (2021). Effect of combined therapy with camel milk-derived exosomes, tamoxifen, and hesperidin on breast cancer. Mol. Cell. Toxicol., 1\u201310.","DOI":"10.1007\/s13273-021-00163-4"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.34172\/ajmb.2022.01","article-title":"Lactophorin in camel milk undergoing specific proteolysis and exhibiting potent anticancer action against human colon and breast cancer cells through ROS generation","volume":"10","author":"Ibrahim","year":"2022","journal-title":"Avicenna J. Med. Biochem."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Taghipour, M.J., Ezzatpanah, H., and Ghahderijani, M. (2023). In vitro and in silico studies for the identification of anti-cancer and antibacterial peptides from camel milk protein hydrolysates. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0288260"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Baothman, O., Ali, M., Alguridi, H., Hosawi, S., Konozy, E., Abu Zeid, I., Ahmad, A., and Altayb, H.N. (2024). Impact of camel milk lactoferrin peptides against breast cancer cells: In silico and in vitro study. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1425504"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1080\/13880209.2017.1309553","article-title":"In vivo antitumour potential of camel\u2019s milk against hepatocellular carcinoma in rats and its improvement of cisplatin renal side effects","volume":"55","author":"Ahmed","year":"2017","journal-title":"Pharm. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12935-018-0534-y","article-title":"Characterization of MCF-12A cell phenotype, response to estrogens, and growth in 3D","volume":"18","author":"Sweeney","year":"2018","journal-title":"Cancer Cell Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"217697","DOI":"10.1016\/j.canlet.2025.217697","article-title":"Glutathione metabolism in ferroptosis and cancer therapy","volume":"621","author":"Xue","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrc3278","article-title":"NRF2 and cancer: The good, the bad and the importance of context","volume":"12","author":"Sporn","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_35","first-page":"94","article-title":"A Review of the Anti-Breast Cancer Activity of Non-Endemic Medicinal Plants in Cyprus","volume":"10","author":"Roshani","year":"2025","journal-title":"Cyprus J. Med. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"23596","DOI":"10.1038\/s41598-026-51303-6","article-title":"A natural coumarin, benjaminin, suppresses proliferation and migration and induces apoptosis in MCF-7 breast cancer cells","volume":"16","author":"Kilus","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Popovici, V., Ozon, E.A., G\u00eerd, C.E., and Lupuliasa, D. (2026). Advances in plant-sourced natural compounds as anticancer agents. Molecules, 31.","DOI":"10.3390\/books978-3-7258-6451-5"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"16081","DOI":"10.1007\/s00210-025-04256-y","article-title":"ML385 increases ferroptosis via inhibiting Nrf2\/HO-1 pathway to enhances the sensitivity of MCF-7 TAMR to tamoxifen","volume":"398","author":"Yuan","year":"2025","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.32604\/or.2025.065755","article-title":"The impact of oxidative stress and the NRF2-KEAP1-ARE signaling pathway on anticancer drug resistance","volume":"33","author":"Verza","year":"2025","journal-title":"Oncol. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1002\/fsn3.2277","article-title":"Inhibition of oxidative stress and apoptosis by camel milk mitigates cyclosporine-induced nephrotoxicity: Targeting Nrf2\/HO-1 and AKT\/eNOS\/NO pathways","volume":"9","author":"Arab","year":"2021","journal-title":"Food Sci. Nutr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.foodchem.2013.03.039","article-title":"Camel milk lactoferrin reduces the proliferation of colorectal cancer cells and exerts antioxidant and DNA damage inhibitory activities","volume":"141","author":"Habib","year":"2013","journal-title":"Food Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.aninu.2018.05.004","article-title":"Potential antioxidant bioactive peptides from camel milk proteins","volume":"4","author":"Ibrahim","year":"2018","journal-title":"Anim. Nutr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments","volume":"55","author":"Bustin","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly 1","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/1087057114521867","article-title":"A new bliss independence model to analyze drug combination data","volume":"19","author":"Zhao","year":"2014","journal-title":"SLAS Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/19466315.2018.1437071","article-title":"Evaluation of drug combination effect using a bliss independence dose\u2013response surface model","volume":"10","author":"Liu","year":"2018","journal-title":"Stat. Biopharm. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8241\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:08:17Z","timestamp":1789549697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":47,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188241"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188241","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}